After a transitional period of several months, the titles of the Ypsomed Holding AG will again be included in the SPI starting 12 May 2015. The SPI is the broad market index for the Swiss equity market. In addition to the Swiss Market Index, the SPI is Switzerland's most closely observed stock market index and contains virtually all of the shares traded on the SIX Swiss Exchange from companies based in Switzerland or the Principality of Liechtenstein.
As the third-largest Indian pharmaceutical company with strong growth and over 45 years of market experience, Lupin is intimately acquainted with the Indian market and the needs of patients with diabetes in India. As such, Lupin is an ideal strategic partner for the Swiss injection system manufacturer Ypsomed.
The long-standing partnership between the French pharmaceutical group Sanofi and the Ypsomed Group will be bolstered by a new major project: starting in late 2016, Ypsomed plans to manufacture components for injection systems on an additional dedicated production line. The additional annual capacity will be in the double-digit millions.
Frank Mengis is to join the executive management of the Ypsomed Group in October 2015, assuming the role of Chief Operating Officer (COO). Mr. Mengis will succeed Dr Benjamin Reinmann, who is leaving the Burgdorf-based medical technology group at his own request.
Over the past few days the quantity of Ypsomed registered shares freely available for trading on the SIX Swiss Exchange, the so-called free float, has exceeded 20% of the total stock of shares. If the free float consistently exceeds the lower limit of 20% over the next three months, then in accordance with the applicable regulations of the SIX Swiss Exchange, Ypsomed will once again be included in the Swiss Performance Index (SPI).